PT Pyridam Farma Tbk (PYFA) Fair Value & Analysis
Healthcare · ID · Market cap 2.1T IDR
Fair value as of: Jun 24, 2026
Analysis
PT Pyridam Farma Tbk (PYFA) currently trades at 206.00 IDR, while our model-based Fair Value estimate is 307.16 IDR — implying the stock looks roughly 49.1% undervalued today. We read business quality at 90/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
About the company
PT Pyridam Farma Tbk engages in the pharmaceutical business in Australia, Indonesia, Philippines, Singapore, and India. The company operates through two segments, Pharmaceutical Products, Esthetic and Toll Manufacturing Services; and Medical Equipment segments. It supplies medical instruments and equipment, including clinical waste, collection swab, collection tube, innerbox DCA, KF94 mask, parafilm, PCR - extraction kit and extractor machine, speciment bag, sterile container, PCR machine- Gentier 48, and tube stopper. The company also provides skin care and beauty products; medical support products; and other consumer health products in the form of syrups, tablets, and capsules; sterile and injection; and sanitizers and antiseptics. In addition, it offers antiseptic solutions, betadine antiseptic skin cleansers, Betadine Vaginal Douche, Cold defense nasal and throat sprays, feminine hygiene, Guardix SG, Mouthwash and Gargle, Salep antiseptic products. PT Pyridam Farma Tbk was found…
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is PT Pyridam Farma Tbk (PYFA) undervalued?
What is the fair value of PYFA?
What is the quality score of PYFA?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.